Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2002

01-02-2002 | Commentary

Elucidation of the potential roles of matrix metalloproteinases in skeletal biology

Author: Stephen M Krane

Published in: Arthritis Research & Therapy | Issue 1/2002

Login to get access

Abstract

Irreversible destruction of joint structures is a major feature of osteoarthritis and rheumatoid arthritis. Fibrillar collagens in bone, cartilage and other soft tissues are critical for optimal joint form and function. Several approaches can be used to ascertain the role of collagenases, matrix metalloproteinases, in proteolysis of joint collagens in arthritis. These approaches include identifying spontaneous genetic disorders of the enzymes and substrates in humans and animals, as well as engineering mutations in the genes that encode these proteins in mice. Insights gained from such studies can be used to design new therapies to interrupt these catabolic events.
Literature
1.
Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M, Stracke J, Clark I: Matrix metalloproteinases in arthritic disease. Arthritis Res. 2002, 4 (suppl 3): S39-S49. 10.1186/ar572.PubMedCentralCrossRefPubMed
2.
Otterness IG, Downs JT, Lane C, Bliven ML, Stukenbrok H, Scampoli DN, Milici AJ, Mezes PS: Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol. 1999, 18: 331-341. 10.1016/S0945-053X(99)00026-8.CrossRefPubMed
3.
Hellio Le Graverand MP, Eggerer J, Sciore P, Reno C, Vignon E, Otterness I, Hart DA: Matrix metalloproteinase-13 expression in rabbit knee joint connective tissues: influence of maturation and response to injury. MatrixBiol. 2000, 19: 431-441. 10.1016/S0945-053X(00)00093-7.
4.
Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002, 295: 2387-2392. 10.1126/science.1067100.CrossRefPubMed
5.
Al Aqeel A, Al Sewairi W, Edress B, Gorlin RJ, Desnick RJ, Martignetti JA: Inherited multicentric osteolysis with arthritis: a variant resembling Torg syndrome in a Saudi family. Am J Med Genet. 2000, 93: 11-18. 10.1002/1096-8628(20000703)93:1<11::AID-AJMG3>3.0.CO;2-3.CrossRefPubMed
6.
Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ: Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet. 2001, 28: 261-265. 10.1038/90100.CrossRefPubMed
7.
Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM: Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000, 24: 45-48. 10.1038/71667.CrossRefPubMed
8.
Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, Mumm S: Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002, 347: 175-184. 10.1056/NEJMoa013096.CrossRefPubMed
9.
Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997, 272: 22389-22392. 10.1074/jbc.272.36.22389.CrossRefPubMed
10.
11.
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999, 99: 81-92. 10.1016/S0092-8674(00)80064-1.CrossRefPubMed
12.
Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA. 2000, 97: 4052-4057. 10.1073/pnas.060037197.PubMedCentralCrossRefPubMed
13.
Wu H, Byrne MH, Stacey A, Goldring MB, Birkhead JR, Jaenisch R, Krane SM: Generation of collagenase-resistant collagen by site-directed mutagenesis of murine pro α1(I) collagen gene. Proc Natl Acad Sci USA. 1990, 87: 5888-5892.PubMedCentralCrossRefPubMed
14.
Liu X, Wu H, Byrne M, Jeffrey J, Krane S, Jaenisch R: A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J Cell Biol. 1995, 130: 227-237. 10.1083/jcb.130.1.227.CrossRefPubMed
15.
Krane SM, Byrne MH, Lemaître V, Henriet P, Jeffrey JJ, Witter JP, Liu X, Wu H, Jaenisch R, Eeckhout Y: Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem. 1996, 271: 28509-28515. 10.1074/jbc.271.45.28509.CrossRefPubMed
16.
Zhao W, Byrne MH, Boyce BF, Krane SM: Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest. 1999, 103: 517-524.PubMedCentralCrossRefPubMed
17.
Chambers TJ, Darby JA, Fuller K: Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res. 1985, 241: 671-675. 10.1007/BF00214590.CrossRefPubMed
18.
Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL: Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem. 1997, 272: 22053-22058. 10.1074/jbc.272.35.22053.CrossRefPubMed
19.
Saftig P, Hunziker E, Everts V, Jones S, Boyde A, Wehmeyer O, Suter A, von Figura K: Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol. 2000, 477: 293-303.CrossRefPubMed
20.
Zhao W, Byrne MH, Wang Y, Krane SM: Inability of collagenase to cleave type I collagen in vivo is associated with osteocyte and osteoblast apoptosis and excessive bone deposition. J Clin Invest. 2000, 106: 941-949.PubMedCentralCrossRefPubMed
21.
Wang Y, Byrne MH, Inada M, Rahman MU, Krane SM: Null mutation in collagenase-3 (matrix metalloproteinase [MMP]-13) affects maturation of growth plates [abstract]. J Bone Mineral Res. 2001, 16 (suppl 1): S141-
22.
Inada M, Wang Y, Byrne MH, Miyaura C, Krane SM: Mice with null mutation in collagenase-3 (matrix metalloproteinase [MMP]-13) exhibit altered bone remodeling and increased bone mass [abstract]. J Bone Mineral Res. 2001, 16 (suppl 1): S149-
Metadata
Title
Elucidation of the potential roles of matrix metalloproteinases in skeletal biology
Author
Stephen M Krane
Publication date
01-02-2002
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2002
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar600

Other articles of this Issue 1/2002

Arthritis Research & Therapy 1/2002 Go to the issue

Announcement

Announcement

Commentary

Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair

Research article

Autologous chondrocyte implantation for cartilage repair: monitoring its success by magnetic resonance imaging and histology

Research article

Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation

Commentary

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients

Research article

Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits